BACKGROUND: Duodenal neuroendocrine tumors are rare and few studies exist to guide surgical management. This study identifies factors associated with recurrence after resection. METHODS: A retrospective, single institution review was performed between 1983 and 2011 on patients with a pathologic diagnosis of duodenal neuroendocrine tumor. Tumor grade was assigned based on WHO 2010 criteria (Ki-67 and mitotic rate). RESULTS: Seventy-five patients were identified that underwent curative resection. This included 12 patients with endoscopic mucosal resection, 34 that had local resection, and 29 that underwent pancreaticoduodenectomy. Two-year and 5-year recurrence-free survival was 84 and 81%, respectively. There were 11 tumor recurrences (either local or distant), and four patients died of their disease (3/4 had high-grade lesions) with an overall median follow-up of 27 months. On univariate analysis, tumor size and tumor grade were identified as being associated with recurrence, but not intervention type, lymph node metastases, ampullary location, or margin status. CONCLUSIONS: Tumor grade and size are associated with recurrence-free survival in duodenal neuroendocrine tumors. When feasible, a less aggressive surgical approach to treat low-grade and low-stage duodenal NETs should be considered.
BACKGROUND: Duodenal neuroendocrine tumors are rare and few studies exist to guide surgical management. This study identifies factors associated with recurrence after resection. METHODS: A retrospective, single institution review was performed between 1983 and 2011 on patients with a pathologic diagnosis of duodenal neuroendocrine tumor. Tumor grade was assigned based on WHO 2010 criteria (Ki-67 and mitotic rate). RESULTS: Seventy-five patients were identified that underwent curative resection. This included 12 patients with endoscopic mucosal resection, 34 that had local resection, and 29 that underwent pancreaticoduodenectomy. Two-year and 5-year recurrence-free survival was 84 and 81%, respectively. There were 11 tumor recurrences (either local or distant), and four patients died of their disease (3/4 had high-grade lesions) with an overall median follow-up of 27 months. On univariate analysis, tumor size and tumor grade were identified as being associated with recurrence, but not intervention type, lymph node metastases, ampullary location, or margin status. CONCLUSIONS:Tumor grade and size are associated with recurrence-free survival in duodenal neuroendocrine tumors. When feasible, a less aggressive surgical approach to treat low-grade and low-stage duodenal NETs should be considered.
Authors: Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue Journal: Am J Surg Pathol Date: 2012-02 Impact factor: 6.394
Authors: John T Mullen; Huamin Wang; James C Yao; Jeffrey H Lee; Nancy D Perrier; Peter W T Pisters; Jeffrey E Lee; Douglas B Evans Journal: Surgery Date: 2005-12 Impact factor: 3.982
Authors: N J Zyromski; M L Kendrick; D M Nagorney; C S Grant; J H Donohue; M B Farnell; G B Thompson; D R Farley; M G Sarr Journal: J Gastrointest Surg Date: 2001 Nov-Dec Impact factor: 3.452
Authors: Timothy Weatherall; Jason Denbo; John Sharpe; Michael Martin; Thomas O'Brien; Rajib Gupta; Kenneth Groshart; Stephen Behrman; Paxton Dickson Journal: World J Surg Date: 2017-03 Impact factor: 3.352
Authors: Catherine G Tran; Scott K Sherman; Mohammed O Suraju; Apoorve Nayyar; Henning Gerke; Rami G El Abiad; Chandrikha Chandrasekharan; Po Hien Ear; Thomas M O'Dorisio; Joseph S Dillon; Andrew M Bellizzi; James R Howe Journal: Ann Surg Oncol Date: 2021-09-13 Impact factor: 5.344
Authors: Epameinondas Dogeas; John L Cameron; Cristopher L Wolfgang; Kenzo Hirose; Ralph H Hruban; Martin A Makary; Timothy A Pawlik; Michael A Choti Journal: J Gastrointest Surg Date: 2017-05-17 Impact factor: 3.452
Authors: Bobby V M Dasari; Sarah Al-Shakhshir; Timothy M Pawlik; Tahir Shah; Ravi Marudanayagam; Robert P Sutcliffe; Darius F Mirza; Paolo Muiesan; Keith J Roberts; John Isaac Journal: J Gastrointest Surg Date: 2018-06-04 Impact factor: 3.452
Authors: R E Rossi; A C Milanetto; V Andreasi; D Campana; J Coppa; G Nappo; M Rinzivillo; P Invernizzi; R Modica; A David; S Partelli; G Lamberti; V Mazzaferro; A Zerbi; F Panzuto; C Pasquali; M Falconi; S Massironi Journal: J Endocrinol Invest Date: 2021-03-02 Impact factor: 4.256